Baidu
map

Lancet:润肤剂和食物均不能降低婴幼儿特应性皮炎风险

2020-03-21 MedSci原创 MedSci原创

使用润肤剂和补充辅食均不能减少12月龄前特应性皮炎的发生率

有研究表明,婴儿早期使用润肤剂可预防特应性皮炎,早期补充食物可以减少高危婴儿食物过敏。近日研究人员考察了在2周龄后开始使用常规润肤剂,或在12-16周龄后开始早期辅食喂养,对一般婴儿群体12个月龄时特应性皮炎风险的影响。
 
研究在挪威和瑞典开展。在2015年至2017年,在18周时接受产前常规超声妊娠筛查的妇女的婴儿在出生时被随机分为对照组,在皮肤护理方面没有具体建议,但建议遵循国家婴儿营养指南(无干预组)、皮肤润肤剂(沐浴露和面霜;皮肤干预组)、花生、牛奶、小麦和鸡蛋的早期辅食喂养(食品干预组)或皮肤和食品联合干预(联合干预组),每周至少4天应用干预措施。研究的主要终点为12个月大的特应性皮炎。
 
2397名新生儿参与研究,其中无干预组596名婴儿中48名(8%)出现特应性皮炎,皮肤干预组575名婴儿中64名(11%)出现特应性皮炎,食物干预组642名婴儿中58名(9%)出现特应性皮炎,而联合干预组583名婴儿中31名(5%)出现特应性皮炎。皮肤润肤剂或早期辅食喂养都不能显著减少特应性皮炎风险,,相比于对照,皮肤干预和食物干预的风险分别降低3.1%和1.0%。干预无安全性问题,组间报告的皮肤症状和体征(包括瘙痒、水肿、皮疹、皮肤干燥和荨麻疹)无显著差异。
 
研究发现,使用润肤剂和补充辅食均不能减少12月龄前特应性皮炎的发生率。
 
原始出处:
 

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1055115, encodeId=fed8105511532, content=<a href='/topic/show?id=c0826e93471' target=_blank style='color:#2F92EE;'>#特应性皮炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=216, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67934, encryptionId=c0826e93471, topicName=特应性皮炎)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Sep 26 21:02:11 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041626, encodeId=39112041626f9, content=<a href='/topic/show?id=7155658e3e9' target=_blank style='color:#2F92EE;'>#润肤剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65873, encryptionId=7155658e3e9, topicName=润肤剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Oct 07 21:48:57 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830536, encodeId=147718305361e, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Sep 19 08:48:57 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416878, encodeId=28f714168e80a, content=<a href='/topic/show?id=27c710101804' target=_blank style='color:#2F92EE;'>#食物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101018, encryptionId=27c710101804, topicName=食物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3a33221853, createdName=yhy100201, createdTime=Mon Mar 23 01:48:57 CST 2020, time=2020-03-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1055115, encodeId=fed8105511532, content=<a href='/topic/show?id=c0826e93471' target=_blank style='color:#2F92EE;'>#特应性皮炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=216, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67934, encryptionId=c0826e93471, topicName=特应性皮炎)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Sep 26 21:02:11 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041626, encodeId=39112041626f9, content=<a href='/topic/show?id=7155658e3e9' target=_blank style='color:#2F92EE;'>#润肤剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65873, encryptionId=7155658e3e9, topicName=润肤剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Oct 07 21:48:57 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830536, encodeId=147718305361e, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Sep 19 08:48:57 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416878, encodeId=28f714168e80a, content=<a href='/topic/show?id=27c710101804' target=_blank style='color:#2F92EE;'>#食物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101018, encryptionId=27c710101804, topicName=食物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3a33221853, createdName=yhy100201, createdTime=Mon Mar 23 01:48:57 CST 2020, time=2020-03-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1055115, encodeId=fed8105511532, content=<a href='/topic/show?id=c0826e93471' target=_blank style='color:#2F92EE;'>#特应性皮炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=216, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67934, encryptionId=c0826e93471, topicName=特应性皮炎)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Sep 26 21:02:11 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041626, encodeId=39112041626f9, content=<a href='/topic/show?id=7155658e3e9' target=_blank style='color:#2F92EE;'>#润肤剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65873, encryptionId=7155658e3e9, topicName=润肤剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Oct 07 21:48:57 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830536, encodeId=147718305361e, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Sep 19 08:48:57 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416878, encodeId=28f714168e80a, content=<a href='/topic/show?id=27c710101804' target=_blank style='color:#2F92EE;'>#食物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101018, encryptionId=27c710101804, topicName=食物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3a33221853, createdName=yhy100201, createdTime=Mon Mar 23 01:48:57 CST 2020, time=2020-03-23, status=1, ipAttribution=)]
    2020-09-19 howi
  4. [GetPortalCommentsPageByObjectIdResponse(id=1055115, encodeId=fed8105511532, content=<a href='/topic/show?id=c0826e93471' target=_blank style='color:#2F92EE;'>#特应性皮炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=216, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67934, encryptionId=c0826e93471, topicName=特应性皮炎)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Sep 26 21:02:11 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041626, encodeId=39112041626f9, content=<a href='/topic/show?id=7155658e3e9' target=_blank style='color:#2F92EE;'>#润肤剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65873, encryptionId=7155658e3e9, topicName=润肤剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Oct 07 21:48:57 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830536, encodeId=147718305361e, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Sep 19 08:48:57 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416878, encodeId=28f714168e80a, content=<a href='/topic/show?id=27c710101804' target=_blank style='color:#2F92EE;'>#食物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101018, encryptionId=27c710101804, topicName=食物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3a33221853, createdName=yhy100201, createdTime=Mon Mar 23 01:48:57 CST 2020, time=2020-03-23, status=1, ipAttribution=)]
    2020-03-23 yhy100201

相关资讯

LEO pharma的IL-13单抗在III期特应性皮炎临床研究中达到实验终点

LEO Pharma宣布,其针对中度至重度特应性皮炎药物tralokinumab在ECZTRA 1、2和3的III期临床试验中已达到所有主要和次要终点。

苏州康乃德生物医药的IL-4Rα单抗CBP-201治疗特应性皮炎,在1b期临床研究中展现出巨大的潜力

苏州康乃德生物医药公布其新型IL-4Rα单抗CBP-201在中度至重度特应性皮炎(AD)患者中的1b期研究结果。结果表明治疗4周后,CBP-201的疗效优于AD当前标准的治疗药物,并具有良好的安全性。该公司预计在2020年第一季度针对中度至重度AD患者启动CBP-201的全球2b期临床研究。

特应性皮炎的治疗进展:ruxolitinib乳膏制剂效果良好

Incyte制药公司今日宣布,在一项III期研究中,选择性JAK1 / JAK2抑制剂ruxolitinib局部乳膏制剂治疗青少年和成人特应性皮炎(AD)达到了其主要终点。

Incyte的JAK1/JAK2抑制剂ruxolitinib乳膏治疗特应性皮炎的第二个III期临床成功

Incyte报道其JAK1 / JAK2抑制剂ruxolitinib的局部乳膏剂达到了轻度至中度特应性皮炎的青少年和成人患者III期TRuE-AD1试验的主要终点和次要终点。ruxolitinib的局部乳膏剂在III期TRuE-AD2研究中也达到了主要终点。

JAK抑制剂baricitinib在III期特应性皮炎研究中显著改善皮肤炎症

礼来公司和Incyte公司近日报道,研究表明,在中度至重度特应性皮炎(AD)患者中评估Olumiant(baricitinib)的III期BREEZE-AD4试验达到了比基线至少改善75%(EASI75)的主要终点。

III期JADE Compare试验:JAK1抑制剂abrocitinib治疗特应性皮炎取得积极结果

辉瑞公司本周三公布了一组数据,表明其研究性JAK1抑制剂abrocitinib治疗成人中度至重度特应性皮炎的III期JADE Compare试验达到了主要终点。

Baidu
map
Baidu
map
Baidu
map